This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded.

Original publication

DOI

10.1046/j.1365-2710.2002.00419.x

Type

Journal article

Journal

Journal of clinical pharmacy and therapeutics

Publication Date

08/2002

Volume

27

Pages

233 - 242

Addresses

Division of Medical Sciences, University of Birmingham, Birmingham, UK.

Keywords

Humans, Death, Sudden, Cardiac, Coronary Disease, Diabetes Complications, Adrenergic beta-Antagonists, Prospective Studies, Physician's Practice Patterns